The TAGGS Assistance Listing Report provides detailed award information for a single Assistance Listing. The data provided is from FY 2008 or from the start date of data collection through the present. For information prior to FY 2008, please use the TAGGS Advanced Search.
In the top display you will see the name of the Assistance Listing, agency, assistance type, and any popular name it might use, along with the 5-digit CFDA number.
Assistance Listings consisting of Direct Payment Awards may not contain links to additional recipient and award information. Direct Payment data is often collected as aggregated payments to a state to protect the personal information of the assistance recipients.
Along with the bar chart broken up by Issue Date or Funding Fiscal Year, there is also an exportable table below that groups by Issue Date or Funding Fiscal Year and shows the recipient name, state, award number, award title and amount from each award action.
By using the radio buttons, you may view data by the Issue Date Fiscal Year of by Funding Fiscal Year. In most cases, the Issue Date and Funding Fiscal Years coincide, although in some cases, delays in issuing an award and award close outs will cause the Issue Date of an award to be outside the of the Funding Fiscal Year.
Table data can be exported by choosing one of the export-format icons located at the top right of the table. Export file formats include:
The two Fiscal Year (FY) viewing options are:
|Issue Date FY||The FY in which the award action Occurred|
|Funding FY||The FY in which the award action Funded|
To enter Keyboard Support and Web Page Reader Support for the report results grid view, you will need to press Ctrl Shift G
|Move through rows||← ↑ ↓ →|
|Next page||SHIFT PAGE DOWN|
|Previous page||SHIFT PAGE UP|
|Move through column headers and data fields||TAB|
|Sort ASC/DESC when a column header is selected||ENTER|
Objectives: To provide support for initiatives funded under the 21st Century Cures Act to support cancer research, such as the development of cancer vaccines, the development of more sensitive diagnostic tests for cancer, immunotherapy and the development of combination therapies, and research that has the potential to transform the scientific field, that has inherently higher risk, and that seeks to address major challenges related to cancer.